eli lilly phase 3 trial retatrutide Today, we shared new data from two trials of retatrutide, our investigational triple agonist. Learn more at our link in bio Lilly's triple agonist, retatrutide, delivered

Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimers and Parkinsons diseases

Weight loss treatments are typically most effective in combination with lifestyle adaptations, including increased physical activity and dietary changes

References Batterham, R

These findings highlight the potential clinical importance of achieving and maintaining weight loss after GLP-1-based treatment initiation. Meeting: European Congress on Obesity 2026 (ECO2026) Never miss a breakthrough: Join the SciTechDaily newsletter

Your healthcare provider will assess your overall health and medical history to determine if this treatment is appropriate for you

Details on how the pen itself works are not yet available